MCC urged to make drug available
In a letter sent last week to the MCC and health minister Dr Aaron Motsoaledi, Medecins Sans Frontieres (Doctors without Borders) and almost 50 doctors and scientists have urged the regulatory body to urgently consider the compassionate use of TMC207, a novel drug currently in Phase III trials.
Compassionate use allows for the dispensing of investigational drugs before they are registered and enter the market.
MSF and other organisations around the world have attempted to use TMC207 for a select few patients with pre-XDR and XDR TB. For many of these patients there is no other hope and TMC207 offers a last chance of survival.
According to MSF it did receive approval from the MCC in August last year to use the drug on compassionate grounds, but Janssen Infectious Diseases (formerly Tibotec) was verbally informed by the MCC to not give MSF TMC207.
MSF and others are now asking the MCC to explain.
South Africa has a serious epidemic of drug resistant (DR) TB ‘ Every year about 10 000 people are diagnosed with multi-drug resistant (MDR) TB, with a substantial proportion suffering XDR TB.
Under the best circumstances, treatment with current, mostly very old drugs is only successful for around 60% of MDR TB and 44% of XDR TB patients.
MSF’s Dr Gilles van Cutsem said it was important to debunk the misguided belief that these patients developed DR TB through delinquency or non-compliance with treatment.
‘Many of these patients were infected directly, through transmission of an already DR TB strain, and have been highly compliant with treatment,’ said Van Cutsem.
TMC207 is a drug that represents the first new class of TB drugs to be developed in 60 years.
The letter urges the MCC to reverse the apparent decision to deny access to the drug and to confirm the compassionate use of TMC207.
‘If the MCC has indeed withdrawn its approval for compassionate use and refuses to reconsider its decision, we then call on them to provide written justification for its actions which have denied potentially life-saving treatment to these patients,’ the letter stated.
The MCC has been given until next Wednesday to approve the drug for compassionate use.
Neither the MCC nor the minister’s spokesperson could be reached for comment.
Author
Health-e News is South Africa's dedicated health news service and home to OurHealth citizen journalism. Follow us on Twitter @HealtheNews
Republish this article
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Unless otherwise noted, you can republish our articles for free under a Creative Commons license. Here’s what you need to know:
You have to credit Health-e News. In the byline, we prefer “Author Name, Publication.” At the top of the text of your story, include a line that reads: “This story was originally published by Health-e News.” You must link the word “Health-e News” to the original URL of the story.
You must include all of the links from our story, including our newsletter sign up link.
If you use canonical metadata, please use the Health-e News URL. For more information about canonical metadata, click here.
You can’t edit our material, except to reflect relative changes in time, location and editorial style. (For example, “yesterday” can be changed to “last week”)
You have no rights to sell, license, syndicate, or otherwise represent yourself as the authorized owner of our material to any third parties. This means that you cannot actively publish or submit our work for syndication to third party platforms or apps like Apple News or Google News. Health-e News understands that publishers cannot fully control when certain third parties automatically summarise or crawl content from publishers’ own sites.
You can’t republish our material wholesale, or automatically; you need to select stories to be republished individually.
If you share republished stories on social media, we’d appreciate being tagged in your posts. You can find us on Twitter @HealthENews, Instagram @healthenews, and Facebook Health-e News Service.
You can grab HTML code for our stories easily. Click on the Creative Commons logo on our stories. You’ll find it with the other share buttons.
If you have any other questions, contact info@health-e.org.za.
MCC urged to make drug available
by Health-e News, Health-e News
April 17, 2012